Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/25
End: 08/31/28
Due: 08/31/29
Phase: N/A
Priority: Normal
Start: 05/20/22
End: 07/31/26
Due: 07/31/27
Phase: N/A
Priority: Normal
Start: 12/06/22
End: 02/05/25
Due: 02/05/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | NCT06939283 | Werewolf Therapeutics, Inc. | user2@example.com | None | 2025-04-30 | 2028-08-31 | 2029-08-31 | - | - | 2025-07-14 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | NCT05479812 | Werewolf Therapeutics, Inc. | user2@example.com | None | 2022-05-20 | 2026-07-31 | 2027-07-31 | - | - | 2025-07-14 |
| WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | NCT05678998 | Werewolf Therapeutics, Inc. | user2@example.com | None | 2022-12-06 | 2025-02-05 | 2026-02-05 | - | - | 2025-07-14 |